#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-inva

ESMO - Eur. Oncology· @myESMO · X·2026-10-23 21:30· 2 天前评分90

正文 · 原文

#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by @y_loriot
🔗 https://ow.ly/TbzF50ZZ0s2

#InsightsbyESMO

1577 浏览 · 14 赞 · 7 转发 · 1 回复

会议摘要

4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study

https://esmocongress.esmo.org

帖内回复

MeDucation@MeDucationai
@myESMO @y_loriot Worth reading next to NIAGARA, where perioperative durvalumab with gemcitabine-cisplatin did improve EFS and OS, so the question for fellows is what differed in design, population and the adjuvant phase rather than whether the class works here.

来源：ESMO - Eur. Oncology · x.com